{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T20:12:50Z","timestamp":1788120770282,"version":"build-2803163510"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare, Japan","doi-asserted-by":"publisher","award":["23AA2003"],"award-info":[{"award-number":["23AA2003"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare, Japan","doi-asserted-by":"publisher","award":["24AA2006"],"award-info":[{"award-number":["24AA2006"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Ceftriaxone is widely used for hospitalized patients with community-acquired pneumonia, but its optimal dosage remains unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively identified patients diagnosed with pneumonia between July 2010 and March 2022 from the Diagnosis Procedure Combination inpatient database in Japan. They were categorized into those receiving 2 or 1\u2005g\/day of ceftriaxone within the first 2\u2005days of hospitalization. The primary outcome was 30-day in-hospital mortality. The secondary outcomes included overall adverse events (composite of biliary tract infection, Clostridioides difficile infection and allergic reactions) and each adverse event. A subgroup analysis was conducted for patients requiring mechanical ventilation. Propensity-score overlap-weighting analysis was used for comparisons.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the 471\u200a694 eligible patients, 63.3% received 2\u2005g\/day and 36.7% received 1\u2005g\/day of ceftriaxone. Propensity-score analysis showed no significant difference in 30-day in-hospital mortality between the two groups [4.5% versus 4.6%; risk difference (RD), \u22120.1%; 95% confidence interval (CI), \u22120.3% to 0.1%; P\u200a=\u200a0.219]. Overall adverse events were slightly higher in the 2\u2005g\/day group (1.9% versus 1.8%; RD, 0.1%; 95% CI, 0.0%\u20130.2%; P\u200a=\u200a0.007), particularly the proportion of C. difficile infection. In the subgroup analysis of patients requiring mechanical ventilation, the 2\u2005g\/day regimen was associated with lower 30-day mortality (17.2% versus 20.4%; RD, \u22123.2%; 95% CI, \u22125.6% to \u22120.9%; P\u200a=\u200a0.006).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>While a ceftriaxone dose exceeding 1\u2005g\/day may not be necessary for routine pneumonia treatment, a 2\u2005g\/day regimen may be considered for patients with severe pneumonia requiring mechanical ventilation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf189","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T07:06:03Z","timestamp":1749539163000},"page":"2194-2202","source":"Crossref","is-referenced-by-count":7,"title":["Outcomes of ceftriaxone 2\u2005g versus 1\u2005g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2480-9018","authenticated-orcid":false,"given":"Jumpei","family":"Taniguchi","sequence":"first","affiliation":[{"name":"Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Aso","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Matsui","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohide","family":"Fushimi","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Informatics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yasunaga","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"2025080100171838800_dkaf189-B1","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/S0140-6736(15)60733-4","article-title":"Community-acquired pneumonia","volume":"386","author":"Prina","year":"2015","journal-title":"Lancet"},{"key":"2025080100171838800_dkaf189-B2","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1056\/NEJMra1312885","article-title":"Community-acquired pneumonia","volume":"371","author":"Musher","year":"2014","journal-title":"N Engl J Med"},{"key":"2025080100171838800_dkaf189-B3","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2025080100171838800_dkaf189-B4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/14787210.2019.1627872","article-title":"Efficacy of ceftriaxone 1","volume":"17","author":"Telles","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025080100171838800_dkaf189-B5","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1186\/s12879-019-4552-8","article-title":"1","volume":"19","author":"Hasegawa","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2025080100171838800_dkaf189-B6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/BF01691490","article-title":"Double-blind randomized study of 1","volume":"14","author":"Segev","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2025080100171838800_dkaf189-B7","doi-asserted-by":"publisher","first-page":"e00066-20","DOI":"10.1128\/AAC.00066-20","article-title":"Comparison of clinical outcomes among intensive care unit patients receiving one or two grams of ceftriaxone daily","volume":"64","author":"Ackerman","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025080100171838800_dkaf189-B8","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s11739-023-03372-y","article-title":"Ceftriaxone 1","volume":"18","author":"Guz","year":"2023","journal-title":"Intern Emerg Med"},{"key":"2025080100171838800_dkaf189-B9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.37737\/ace.1.3_76","article-title":"Real world data in Japan: chapter II the diagnosis procedure combination database","volume":"1","author":"Yasunaga","year":"2019","journal-title":"Ann Clin Epidemiol"},{"key":"2025080100171838800_dkaf189-B10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.37737\/ace.24015","article-title":"Updated information on the diagnosis procedure combination data","volume":"6","author":"Yasunaga","year":"2024","journal-title":"Ann Clin Epidemiol"},{"key":"2025080100171838800_dkaf189-B11","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.je.2016.09.009","article-title":"Validity of diagnoses, procedures, and laboratory data in Japanese administrative data","volume":"27","author":"Yamana","year":"2017","journal-title":"J Epidemiol"},{"key":"2025080100171838800_dkaf189-B12","first-page":"61","article-title":"Functional evaluation: the Barthel index","volume":"14","author":"Mahoney","year":"1965","journal-title":"Md State Med J"},{"key":"2025080100171838800_dkaf189-B13","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"2025080100171838800_dkaf189-B14","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1136\/thx.2009.121434","article-title":"BTS guidelines for the management of community acquired pneumonia in adults: update 2009","volume":"64","author":"Lim","year":"2009","journal-title":"Thorax"},{"key":"2025080100171838800_dkaf189-B15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2169\/internalmedicine.45.1691","article-title":"The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations","volume":"45","author":"Miyashita","year":"2006","journal-title":"Intern Med"},{"key":"2025080100171838800_dkaf189-B16","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/j.1440-1843.2008.01329.x","article-title":"Comparison of severity scoring systems A-DROP and CURB-65 for community-acquired pneumonia","volume":"13","author":"Shindo","year":"2008","journal-title":"Respirology"},{"key":"2025080100171838800_dkaf189-B17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/1471-2334-14-247","article-title":"A systematic review for pursuing the presence of antibiotic associated enterocolitis caused by methicillin resistant Staphylococcus aureus","volume":"14","author":"Iwata","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2025080100171838800_dkaf189-B18","doi-asserted-by":"publisher","first-page":"l5657","DOI":"10.1136\/bmj.l5657","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"},{"key":"2025080100171838800_dkaf189-B19","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial","volume":"323","author":"Thomas","year":"2020","journal-title":"JAMA"},{"key":"2025080100171838800_dkaf189-B20","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"2025080100171838800_dkaf189-B21","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"2025080100171838800_dkaf189-B22","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S0924-8579(01)00322-3","article-title":"Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogens","volume":"17","author":"Owens","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"2025080100171838800_dkaf189-B23","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1128\/AAC.36.12.2804","article-title":"Pharmacokinetics and tissue penetration of a single dose of ceftriaxone (1,000","volume":"36","author":"Martin","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"2025080100171838800_dkaf189-B24","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/jac\/47.4.421","article-title":"The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients","volume":"47","author":"Joynt","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"2025080100171838800_dkaf189-B25","doi-asserted-by":"publisher","first-page":"6165","DOI":"10.1128\/AAC.00951-13","article-title":"Protein binding of \u03b2-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?","volume":"57","author":"Wong","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2025080100171838800_dkaf189-B26","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/bcp.12636","article-title":"Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients","volume":"80","author":"Schleibinger","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2025080100171838800_dkaf189-B27","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1093\/jac\/dkab091","article-title":"Antibiotics and healthcare facility-associated Clostridioides difficile infection: systematic review and meta-analysis 2020 update","volume":"76","author":"Slimings","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2025080100171838800_dkaf189-B28","doi-asserted-by":"publisher","first-page":"ofad413","DOI":"10.1093\/ofid\/ofad413","article-title":"Comparison of different antibiotics and the risk for community-associated Clostridioides difficile infection: a case\u2013control study","volume":"10","author":"Miller","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2025080100171838800_dkaf189-B29","first-page":"225","article-title":"An unusual case of delayed-type hypersensitivity to ceftriaxone and meropenem","volume":"47","author":"Dias de Castro","year":"2015","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"2025080100171838800_dkaf189-B30","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1093\/cid\/ciad523","article-title":"Clinical outcomes and management of NAAT-positive\/toxin-negative Clostridioides difficile infection: a systematic review and meta-analysis","volume":"78","author":"Prosty","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025080100171838800_dkaf189-B31","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","article-title":"ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections","volume":"116","author":"Kelly","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"2025080100171838800_dkaf189-B32","doi-asserted-by":"publisher","first-page":"102516","DOI":"10.1016\/j.jiac.2024.09.005","article-title":"Comparative prospective cohort study of efficacy and safety according to dosage and administration of ceftriaxone for community-acquired pneumonia","volume":"31","author":"Nakanishi","year":"2025","journal-title":"J Infect Chemother"},{"key":"2025080100171838800_dkaf189-B33","volume-title":"Nippon AMR One Health Report (NAOR) 2023","author":"Ministry of Health, Labour and Welfare","year":"2023"},{"key":"2025080100171838800_dkaf189-B34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.35772\/ghm.2019.01017","article-title":"National action plan on antimicrobial resistance (AMR) 2016\u20132020 and relevant activities in Japan","volume":"1","author":"Ohmagari","year":"2019","journal-title":"Glob Health Med"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/8\/2194\/63461970\/dkaf189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/8\/2194\/63461970\/dkaf189.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T04:17:23Z","timestamp":1754021843000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/8\/2194\/8159641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,6,10]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf189","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,6,10]]}}}